Impact of anticancer treatment on recurrent obstruction in covered metallic stents for malignant biliary obstruction
Authors:
- 25 January 2013
- journal article
- research article
- Published by Springer Nature in Journal of Gastroenterology
- Vol. 48 (11) , 1293-1299
Abstract
In patients with unresectable malignant biliary obstruction (MBO), anticancer treatment is often administered. The impact of anticancer treatment on recurrent biliary obstruction in covered self-expandable metallic stents (SEMS) has not been fully elucidated. Data on 279 patients enrolled in a multicenter prospective cohort study of two different covered SEMS for distal MBO, WATCH study (141 partially covered WallFlex stents and 138 partially covered Wallstents) were retrospectively analyzed. The rates and causes of recurrent biliary obstruction (stent occlusion or migration) were compared between anticancer treatment group (n = 173) and best supportive care alone (BSC) group (n = 106). Cumulative time and prognostic factors for recurrent biliary obstruction were analyzed, using a proportional hazards model with death without recurrent biliary obstruction as a competing risk. The overall rate (43 vs. 25 %, P = 0.002) and the cumulative incidence (16.1 vs. 8.2, 27.9 vs. 18.9 and 44.1 vs. 26.6 % at 3, 6 and 12 months, P = 0.030 by Gray’s test) of recurrent biliary obstruction were significantly higher in anticancer treatment group compared with BSC group. The multivariate analysis revealed anticancer treatment [subdistribution hazard ratio (SHR) 1.93, P = 0.007) as well as the use of a partially covered WallFlex stent (SHR 0.65, P = 0.049) as prognostic factors. Anticancer treatment was a risk factor for recurrent biliary obstruction in covered SEMS for distal MBO. The superiority of a partially covered WallFlex stent was again confirmed in this competing risk analysis; UMIN-CTR: UMIN000002293.Keywords
This publication has 29 references indexed in Scilit:
- Better stent function with chemotherapy: effects of chemotherapy or just a better prognosis?Gastrointestinal Endoscopy, 2012
- A Multicenter Prospective Study of the Short-Term Outcome of a Newly Developed Partially Covered Self-Expandable Metallic Biliary Stent (WallFlex®)Digestive Diseases and Sciences, 2011
- A randomized trial comparing uncovered and partially covered self-expandable metal stents in the palliation of distal malignant biliary obstructionGastrointestinal Endoscopy, 2010
- Covered versus uncovered self-expandable nitinol stents in the palliative treatment of malignant distal biliary obstruction: results from a randomized, multicenter studyGastrointestinal Endoscopy, 2010
- Efficacy and Safety of Metallic Stents in Patients With Unresectable Pancreatic Cancer Receiving GemcitabinePancreas, 2008
- Efficacy and safety of the covered Wallstent in patients with distal malignant biliary obstructionGastrointestinal Endoscopy, 2005
- Adjuvant therapies using biliary stenting for malignant biliary obstructionJournal of Hepato-Biliary-Pancreatic Surgery, 2001
- A Proportional Hazards Model for the Subdistribution of a Competing RiskJournal of the American Statistical Association, 1999
- Bile duct stents: Is there an increased rate of complications in patients receiving chemotherapy?European Journal of Cancer, 1997
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958